David Rosenberg, MD
Neurology · Los Alamitos, CANPI 1013959097
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $993 of the $1,399 with a category attached, or 71.0%. 14 manufacturers reported payments, led by AbbVie at 42.5% of the total. Reporting peaked in 2021 at $611 and has fallen 87.3% since, to $78 in 2025. That places this record below the midpoint for neurology clinicians in CA, where the typical reported total is $885.
Across 23 payments — averaging $60.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$595
- Merz North America, Inc.$204
- Jazz Pharmaceuticals Inc.$150
- AstraZeneca$119
- Galderma Laboratories, L.p.$107
- Acell, Inc.$48
- plus $176 from 8 others
Across 394 payments — averaging $16,117 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$4.1M
- Bavarian Nordic A/s$751K
- Sage Therapeutics, LLC$403K
- AbbVie$249K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$249K
- Biohaven Pharmaceuticals, Inc.$231K
- plus $377K from 9 others
What the payments were for
- Travel & lodging$40629%
- Food & beverage$99371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $595 |
| Merz North America, Inc. | 3 | $204 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| AstraZeneca | 1 | $119 |
| Galderma Laboratories, L.p. | 6 | $107 |
| Acell, Inc. | 1 | $48 |
| Greenwich Biosciences, Inc. | 1 | $33 |
| Strongbridge US Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Adamas Pharmaceuticals, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Medtronic | 1 | $17 |
| Lemaitre Vascular, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,399 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Los Alamitos
- Nirav PatelLos Alamitos$755K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.